title: Phase I study of a novel recombinant human soluble thrombomodulin, ART-123.
authors.affiliation: University of North Carolina School of Medicine, Department of Medicine, Division of Hematology-Oncology, Chapel Hill, NC 27599, USA. smoll@med.unc.edu
authors.forename: S
authors.initials: S
authors.lastname: Moll
authors.forename: C
authors.initials: C
authors.lastname: Lindley
authors.forename: S
authors.initials: S
authors.lastname: Pescatore
authors.forename: D
authors.initials: D
authors.lastname: Morrison
authors.forename: K
authors.initials: K
authors.lastname: Tsuruta
authors.forename: M
authors.initials: M
authors.lastname: Mohri
authors.forename: M
authors.initials: M
authors.lastname: Serada
authors.forename: M
authors.initials: M
authors.lastname: Sata
authors.forename: H
authors.initials: H
authors.lastname: Shimizu
authors.forename: K
authors.initials: K
authors.lastname: Yamada
authors.forename: G C
authors.initials: GC
authors.lastname: White
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D001780:Blood Coagulation Tests; D004305:Dose-Response Relationship, Drug; D005260:Female; D006207:Half-Life; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010599:Pharmacokinetics; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012995:Solubility; D018180:Thrombomodulin / Q000008:administration & dosage*; D013925:Thromboplastin / Q000037:antagonists & inhibitors
chemical_list: C472045:ART123; D000925:Anticoagulants; D011994:Recombinant Proteins; D018180:Thrombomodulin; D013925:Thromboplastin